News

Weekly Policy Update: CBSA Co-Hosts Aurora Facility Tour for State Senator Rhonda Fields

Friday, October 25, 2019

This week CBSA partnered with CSL Behring to host state Senator Rhonda Fields for a tour of the CSL Plasma Collection Center in Aurora. On the tour, the collection center managers were able to show Senator Fields the process for donating plasma – which is the first step in the process of manufacturing plasma-derived therapies that patients rely on every day. Plasma-derived therapies replace missing or deficient proteins that allow people to live healthy and more productive lives, including individuals living with alpha-1 disease, primary immunodeficiency disease, hereditary angioedema, and other rare conditions.  

Weekly Policy Update: CBSA Partners with LivaNova to host Rep. Brianna Titone

Friday, October 18, 2019

This week CBSA partnered with LivaNova to host state Rep. Brianna Titone for a tour and employee town hall at the company’s Arvada facility. It was a great opportunity to showcase the devices that are designed and manufactured at the Colorado plant and highlight the growth and development that is taking place there. We also had the chance to talk to Representative Titone about the life sciences ecosystem in Colorado, and we look forward to continuing to work with her on the issues that matter to our members. 

Weekly Policy Update: State Releases Draft Proposal for Public Health Insurance Option

Friday, October 11, 2019

  

Weekly Policy Update: CBSA Urges Congress to Reject Proposals that Adopt Foreign Price Controls

Friday, October 04, 2019

CBSA is committed to ensuring patients have access to the treatments they need. We appreciate the bipartisan efforts underway by the Trump Administration and Congress to provide patients relief from high out-of-pocket costs, but we are deeply concerned about recent legislative proposals like H.R. 3 that aim to introduce international reference pricing and foreign price controls as a strategy to reduce prescription drug costs.

Foreign countries are able to pay less for drugs by denying access to certain therapies for many patients who need them. In the United States, patients have access to almost 90 percent of new drugs launched since 2011. In the countries that Congress is hoping to mirror with H.R. 3, 50 percent or fewer new therapies are made available to patients. And many times those patients have to wait years before those novel treatments are available. If the United States implemented foreign price controls, patient choice and patient access to innovative therapies would be severely limited.

These recent proposals also jeopardize the innovative biopharmaceutical sector in the United States, a sector that already takes on huge risks and significant investments. The suggestion of foreign price controls will scare away investment in the life sciences, and that money will go to an industry that is less risky and offers a greater return. Capital flowing out of the sector will quickly result in lack of innovation and fewer breakthrough treatments for patients.

In the coming weeks the U.S. House of Representatives is expected to vote on H.R. 3, a proposal that would adopt the health care policies set by foreign countries that lead to fewer innovative medicines and restricted patient access.

CLICK HERE TO CONTACT YOUR ELECTED OFFICIALS TODAY AND TELL THEM TO OPPOSE H.R. 3.

Patients deserve access to the life-saving therapies of today and tomorrow.



 
Continue Reading

Weekly Policy Update: CBSA Submits Comment Letter to CMS Advocating for Patient Access to Timely Precision Diagnostic Information

Friday, September 27, 2019

In July the Centers for Medicare and Medicaid Services (CMS) issued the CY 2020 Hospital Outpatient Prospective Payment System (HOPPS) Proposed Rule, which included concerning proposed revisions to the current Laboratory Date of Service (DOS) policy. After engaging our members about the potential impact of these changes, CBSA submitted a comment letter to CMS this week expressing that if finalized, the proposed revisions would significantly limit patient access to clinically important diagnostic testing information.  

Weekly Policy Update: House Speaker Nancy Pelosi Releases Proposal on Prescription Drug Pricing

Monday, September 23, 2019

On September 19, House Speaker Nancy Pelosi released a long-anticipated proposal intended to reduce prescription drug prices. H.R. 3, the Lower Drug Costs Now Act of 2019, includes the following provisions:

  • Allows Medicare to negotiate prescription drug prices for 25 – 250 brand-named drugs per year. The price cap negotiated by Medicare would be no more than 1.2 times the volume-weighted average price of six other countries and would also apply to the commercial insurance market. If a manufacturer refuses to negotiate with Medicare or leaves the negotiation before agreeing to a “maximum fair price,” they will be assessed an escalating excise tax levied on their annual gross sales – starting at 65% and increasing by 10% every quarter the manufacturer is out of compliance, until they reach 95%.
  • Imposes an inflation rebate on all drugs in Medicare Part B and Part D. This means if a manufacturer raises the price of a drug above the rate of inflation since 2016, they can either lower the price or pay the entire price over inflation in the form of a rebate back to the U.S. Treasury.
  • Creates a cap on the costs for prescription drugs for Medicare Part D beneficiaries by setting an annual out-of-pocket limit of $2,000.
  • Restructures the liability in the coverage phases of Medicare Part D. Manufacturers would be required to pay 10% of the cost in the initial coverage phase and 30% of the costs in the catastrophic coverage phase.

Over the past few months, CBSA has expressed opposition to a number of these provisions that we’ve seen included in other legislative proposals, including allowing government negotiation in Medicare and imposing inflation rebates in Medicare Part B and D. Such proposals would destabilize the market- based system that determines the value of medicines and deter investment in life sciences innovation.

We will continue coordinate with members and industry partners to voice our strong concerns about these proposals and educate lawmakers about how these policies will limit patient access and stifle medical innovation.

A legislative hearing on the bill is set for Wednesday, September 25 in the House Energy and Commerce Committee’s Subcommittee on Health. More information can be found here.

 
Continue Reading

Weekly Policy Update: Zimmer Biomet Spine Hosts Congressman Ed Perlmutter at Westminster Facility

Friday, September 13, 2019

At the end of August, Congressman Ed Perlmutter (CO-07) visited Zimmer Biomet Spine in Westminster to tour the medical education training facilities, biomechanics labs, and manufacturing area. Following the tour, the Congressman joined Zimmer Biomet staff for a discussion about products and markets, legislative priorities, and other issues of common interest.
 

Weekly Policy Update: CBSA Hosts Congressman Jason Crow (CO-06)

Friday, August 30, 2019

  

Weekly Policy Update: CBSA Meets with Executive Director of OEDIT

Monday, August 26, 2019

  

Weekly Policy Update: Take Action! Join a New Letter Urging Congress to Prioritize Repeal of the Medical Device Tax

Monday, August 19, 2019